PAR 4.76% 20.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-1826

  1. 249 Posts.
    lightbulb Created with Sketch. 23
    Thanks guys, much appreciated. I'll continue to research, however from what i can see the drug is clearly very effective. Is the recent share price slide thought to be due to investors losing interest with the long timeframe for assessment and eventual approval?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.